Back to today’s briefing

Story perspectives

Semaglutide Revolutionizes Liver Health in MASH Patients

5/15/2025

49 11

Summary

Story summary

A groundbreaking study in The New England Journal of Medicine reveals that semaglutide, a medication for obesity and diabetes, offers remarkable benefits for liver health in patients with metabolic dysfunction-associated steatohepatitis (MASH). After 72 weeks, an impressive 62.9% of participants saw a reduction in liver fat and inflammation, highlighting its potential as a powerful treatment for MASH.

1 of 1

Story summary

A groundbreaking study in The New England Journal of Medicine reveals that semaglutide, a medication for obesity and diabetes, offers remarkable benefits for liver health in patients with metabolic dysfunction-associated steatohepatitis (MASH). After 72 weeks, an impressive 62.9% of participants saw a reduction in liver fat and inflammation, highlighting its potential as a powerful treatment for MASH.